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effects in GN. Background. Activators of peroxisome proliferator activated receptor ␥ (PPAR␥) have been shown to modulate chemokine expression in isolated monocytes/macrophages (M/M) and to exert anti-inflammatory effects in some models of experimental
The peroxisome proliferator-activated receptor ␥ inflammatory diseases. We evaluated the effects of different (PPAR␥) is a member of the family of nuclear receptors forms of PPAR␥ activators in a model of experimental glomerof ligand-activated transcription factors that include steulonephritis (GN) in rats.
Methods. GN was induced in rats by application of an antiroid, retinoid, and thyroid hormone receptors [1] . The thymocyte antibody (ATS). Nephritic rats were treated with PPARs form heterodimers with the 9-cis retinoic acid retwo synthetic PPAR␥ ligands of the thiazolidinedione (TZD) ceptor, RXRa, and bind to characteristic DNA sequences group, troglitazone (200 mg/kg/day) and ciglitazone (100 mg/kg/ termed peroxisome proliferator response elements (PPRE) day), and with a natural ligand 15d-PGJ 2 (1.5 mg/day). Twentylocated in the promoter region of target genes. Three four hours after induction of the GN, the glomerular mRNA isoforms of PPAR (PPAR␣, PPAR␤ and PPAR␥) have expression of the chemokine monocyte chemoattractant protein-1 (MCP-1) and the cognate chemokine receptor CCR-2 been described [2] . PPAR␥ is expressed at high levels were examined by Northern blotting and RT-PCR. The gloin adipose tissues and plays a crucial role in lipid metabomerular M/M infiltration was determined by immunohistology.
lism and glucose homeostasis [3] . A structurally diverse
The activation of the transcription factors PPAR␥, nuclear group of compounds, naturally occurring fatty acid derivfactor-B (NF-B) and activator protein-1 (AP-1) in glomeruli atives, eicosanoids (such as 15d-PGJ 2 ) and synthetic molwas analyzed by electrophoretic mobility shift assay. receptors [4, 5] . PPAR␥ ligands of the TZD group lower and AP-1 DNA binding but did not affect NF-B binding.
blood glucose levels and are in use as potent anti-diabetic TZD enhanced glomerular MCP-1 expression and increased drugs in humans [6] . They protect against the developglomerular M/M recruitment. In contrast, 15d-PGJ 2 attenuated NF-B activation and did not affect AP-1 activity or MCP-1 ment and progression of diabetic nephropathy [7, 8] and expression.
nondiabetic glomerulosclerosis in rats [9] . Recent reports of inflammatory cytokines and chemokines [10] [11] [12] . Controversy exists, however, since other studies demonstrated pro-inflammatory rather than anti-inflammatory In several forms of glomerulonephritis, the activation METHODS and infiltration of M/M in glomeruli and the tubulointerInduction of glomerulonephritis and stitium is a typical pathological feature closely correlated experimental design to disease progression. The recruitment of M/M into inImmune-mediated mesangial cell injury was induced jured tissues is largely dependent on a group of cytokines in male Wistar rats (180 to 200 g/BW) by IV injection called chemokines [17] . Among these chemokines, monoof an anti-rat-thymocyte antiserum (ATS). ATS was incyte chemoattractant protein-1 (MCP-1) [18] is an imduced in rabbits by repeated immunization with thymoportant mediator for M/M infiltration in several forms cytes from Lewis rats as described earlier [22] . of experimental glomerulonephritis [19] [20] [21] .
Eight different groups of animals (total N ϭ 140) were To investigate a possible role of different PPAR␥ activators in the modulation of M/M attraction into glomerstudied at 24 hours after nephritis induction. For each uli and on the course of GN, the effects of troglitazone, experimental setup groups of four animals were comciglitazone and 15d-PGJ 2 were studied in a rat model of pared, the experimental setup was repeated at least two mesangial immune GN.
times. Experiments with troglitazone were performed Our results demonstrate that stimulation of PPAR␥ four times. Control rats (N ϭ 32) received 0.5 mL/100 g through troglitazone and ciglitazone increases MCP-1 BW of non-antibody IgG intravenously. Nephritic rats expression and M/M recruitment in the early stage of a (N ϭ 32) received 0.5 mL/100 g BW of ATS intraverat model of mesangial immune glomerulonephritis, and nously. Control and nephritic rats treated with troglitasuggest that these effects are partly mediated through zone (N ϭ 52) received 20, 50, 200 and 500 mg/kg BW of an enhanced binding activity of the nuclear transcription troglitazone per day in a 1% methylcellulose suspension factor AP-1. In contrast, application of 15d-PGJ 2 reduces orally. Control and nephritic rats treated with ciglitazone NF-B activation and did not exert pro-inflammatory (N ϭ 12) received 100 mg/kg BW ciglitazone orally per effects. These results demonstrate the complex role of day in a 1% methylcellulose suspension orally. Control PPAR␥ activation in the setting of inflammatory disease and nephritic rats treated with 15d-PGJ 2 (N ϭ 12) reand underscore the need of a careful evaluation of possible deleterious effects of PPAR␥ activators in GN. ceived 1.5 mg/kg BW 15d-PGJ 2 daily in normal saline subcutaneously. In all groups medication was started 24 bers of ED-1 and PCNA positive cells are given per hours before the induction of the disease and continued glomerular cross section as means Ϯ SEM. until sacrifice.
Isolation of glomeruli, preparation of total RNA, and Northern blot hybridization Histology
Glomeruli were isolated by a fractional sieving techRenal tissue was fixed in 4% buffered formaldehyde. nique using 90 m and 53 m mesh wire sieves, cellular Paraffin embedded sections (2 m) were either stained RNA from glomeruli was isolated and 10 to 20 g of with an antibody directed against the monocyte specific total RNA was used for Northern blot analysis. A rat marker ED-1 (Chemicon International, Temecula, CA, MCP-1 cDNA fragment was used for hybridization. USA) to evaluate glomerular M/M infiltration or with Membranes were rehybridized with a cDNA probe for an antibody against the proliferative cell nuclear antigen human 18 S RNA to account for small loading and trans-(PCNA; Dakopatts M879, Hamburg, Germany). Tissue fer variabilities. Densities on exposed films were quantisections were developed with the alkaline phosphatase fied using a phosphoimager Bio-Rad-GS-363 System anti-alkaline phosphatase (APAAP) technique. ED-1 (multi-analyst software; Bio-Rad, Munich, Germany). and PCNA positive cells in 50 glomeruli per kidney were Data analysis of Northern blot experiments was percounted by light microscopy in a blinded fashion where formed using three independent sets of experiments, and the tissue source was unknown. Four different kidneys of each group were evaluated at 24 hours. The cell numthe results are shown as mean Ϯ SEM. 
RT-PCR
platform at 400 rpm for 15 minutes. Nuclear protein extracts were obtained after centrifugation at 15,000 ϫ For reverse transcription-polymerase chain reaction g for five minutes. Protein concentration was determined (RT-PCR) 1 g of total RNA, 4 L 5ϫ First strand using DC protein assay (Bio-Rad Laboratories), aliquots buffer, 1 L dNTPs (20 mmol/L), 2 L dithiothreitol were stored at Ϫ80ЊC. EMSA was performed using a (DTT; 0.1 mol/L), 0.4 L poly(dT) primer (1 mg/mL; PPAR␥ (5Ј-GGA CCA GGA CAA AGG TCA CGT Pharmacia, Freiburg, Germany), 0.4 L RNasin (Pro-TC 3Ј) [25] , NF-B (5Ј-AGT TGA GGG GAC TTT mega, Madison, WI, USA), and 1 L Molony-murine CCC AGG C 3Ј) (Promega), and AP-1 (5Ј CGC TTG leukemia virus (M-MLV) reverse transcriptase (2 U/mL; ATG AGT CAG CCG GAA 3Ј) (Promega) consensus Gibco BRL, Eggenstein, Germany) per sample were oligonucleotide probe that was end-labeled with ␣ 32 P mixed. The RT reaction was carried out for two hours ATP (3,000 Ci/mmol; Amersham Pharmacia Biotech, at 37ЊC. Exact primer sequences for CCR-2 and MCP-1
Freiburg, Germany) according to the manufacturer's inare available from the authors. Five microliters of each structions. One to 5 g of nuclear protein was incubated RT reaction sample was added to 29. were performed by adding unlabeled PPAR␥, NF-B shown) using the following temperature profile: 95ЊC for and AP-1 consensus oligonucleotides in 100-fold molar 10 seconds, 57ЊC for 20 seconds, and 72ЊC for 30 seconds.
excess to the binding reaction. The DNA-protein com-RNA samples were also analyzed for the expression of plexes were subjected to electrophoresis on a 4% polythe housekeeping gene GAPDH as described earlier acrylamide gel containing 2.5% glycerol, 6.7 mmol/L [23] . Amplified cDNA fragments were separated on a Tris-HCl (pH 7.5), 3.3 mmol/L sodium acetate and 0.1 1.5% agarose gel containing 1 mg/mL ethidium bromide, mmol/L EDTA for 2.5 hours at 15ЊC. The gel was then and the gel was photographed under UV light using a vacuum-dried and autoradiography was performed. ExPolaroid 655 film. The amplified cDNA of the predicted posed EMSA films were quantified using a phosphosize was isolated, subcloned, and sequenced to confirm imager Bio-Rad-GS-363 (multi-analyst software) and corspecificity of the reaction. To control for genomic DNA rected to the density of the probe. artifacts, a control PCR without RT was performed. Exposed films were quantified using a phosphoimager BioRad-GS-363 (multi-analyst software).
Western blotting for PCNA For Western blotting glomeruli were isolated and centrifuged in 1 ϫ PBS. The pellet was resuspended in 100 Glomerular nuclear mini-extracts and EMSA L of Laemmli buffer [33% vol/vol 0.5 mmol/L TrisKidneys were harvested after in situ perfusion with HCl pH 6.8, 66% vol/vol sodium dodecyl sulfate (SDS) 100 mL of sterile phosphate buffered saline (PBS). We 10%]. Samples were boiled for 10 minutes and centriadapted a method described by Sakurai et al to prepare fuged. The protein concentration was determined with the nuclear mini-extracts and run the electrophoretic moa modified Lowry method (Protein DC-assay; Bio-Rad). bility shift assay (EMSA) [24] . For extraction of nuclear To equal amounts of protein (80 g) buffer, 25 mmol/L Tris, 40 mmol/L 6-amionohexane acid, the suspension was chilled on ice for 15 minutes. Twenty-20% methanol) for 45 minutes at 0.8 mA/cm 2 to a nitrofive microliters of 10% Noniodet P-40 were added, the cellulose membrane (Hybond ECL; Amersham). The homogenate vigorously mixed for 10 seconds and cenmembrane was blocked in 5% nonfat dry milk in washing trifuged at 15.000 ϫ g for five minutes. buffer for 3 ϫ 10 minutes, the secondary antibody, a nescence detection of peroxidase was performed with the enhanced chemiluminescence (ECL) system according to rabbit anti-goat-immunoglobin G conjugated to horseradish-peroxidase (Southern Biotechnology, Atlanta, GA, the manufacturer's recommendations (Amersham). Films were exposed 2 to 10 minutes at room temperature. USA) was added at a concentration of 1:1000. The lumi- nephritis activated glomerular nuclear protein binding Statistical analysis of NF-B and AP-1, whereas glomerular PPAR␥ DNA Results are expressed as mean ϩ SEM unless stated binding was reduced in nephritic rats at 24 hours (Fig. 3) . otherwise. Statistical significance was defined as P Ͻ As expected, PPAR␥ binding was enhanced in animals 0.05. We applied Wilcoxon-Mann-Whitney test to comtreated with troglitazone, ciglitazone and 15d-PGJ 2 in pare two distinct treatment groups (that is, nephritic vs.
control and nephritis groups. In nephritic animals troglicontrol or nephritic vs. treated nephritic animals).
tazone and ciglitazone treatment enhanced glomerular nuclear binding of AP-1, but did not influence glomerular NF-B activity. In contrast, treatment of nephritic rats RESULTS with 15d-PGJ 2 did not lead to an increase in AP-1 bindInduction of glomerulonephritis and treatment with ing, but reduced NF-B binding. Application of troglita-PPAR␥ agonists zone, ciglitazone and 15d-PGJ 2 to control animals did not Glomerular chemokine and chemokine receptor expresinfluence glomerular DNA binding of the transcription sion. Glomerular MCP-1 mRNA expression increased factors NF-B and AP-1 in comparison to the untreated significantly in nephritic animals at 24 hours after induccontrol group. tion of the disease when compared with control animals Glomerular monocyte/macrophage infiltration. Induc- (Fig. 1A) . Treatment with troglitazone and ciglitazone tion of glomerulonephritis resulted in a significant infurther enhanced up-regulation of MCP-1 mRNA at 24 crease in glomerular monocyte infiltration from 0.3 Ϯ hours (Figs. 1A and 2A) . The mRNA expression of the 0.07 cells/glomerular cross section (c/gcs) in controls to chemokine receptor CCR-2 (receptor for MCP-1) also 2.95 Ϯ 0.39 cells in nephritic rats at 24 hours (P Ͻ 0.01; was up-regulated 24 hours after induction of the disease Fig. 4 A, B and Fig. 5 ). Treatment of nephritic animals (Figs. 1B and 2B ). Troglitazone and ciglitazone further with troglitazone and ciglitazone further enhanced gloenhanced the CCR-2 expression. In contrast, 15d-PGJ 2 merular monocyte recruitment at 24 hours (nephritis ϩ did not up-regulate MCP-1 and CCR-2 expression (Fig. 2) .
Tro concentrations between 20 and 500 mg/kg BW lead to that PPAR␥ ligands may modulate chemokine expression and inflammatory responses [10, 11] as well as transan increased glomerular M/M infiltration and glomerular differentiate monocytes into macrophage foam cells [12] . MCP-1 RNA expression (Fig. 6) .
In studies on isolated monocytes/macrophages treatment Effect of troglitazone on glomerular cell proliferation.
with PPAR␥ agonists reduced tumor necrosis factor-␣ Glomerular cell proliferation was assessed by PCNA (TNF-␣), interleukin (IL)-1␤ and IL-6 synthesis induced Western blotting (Fig. 7) and immunohistologic staining by phorbol ester [10] , and inhibited the expression of of tissue for PCNA (Figs. 8 and 9 ). As expected, there several inflammatory response genes induced by interwas an increase in PCNA protein formation in nephritic feron-␥ (IFN-␥) [11] . In a mouse model of inflammatory animals 24 hours and 5 days after induction of nephritis bowel disease PPAR␥ agonists attenuate cytokine gene when compared to the control and troglitazone treated expression and reduce colonic inflammation after seven animals (Figs. 7 to 9 ). Treatment of nephritic rats with days [33] . troglitazone (200 mg/kg BW/day) lead to a small deWe were therefore interested in examining a possible crease of cell proliferation at both time points studied role of different forms of PPAR␥ activators in a model (Figs. 7 to 9 ). However the effect is not statistically sigof glomerulonephritis characterized by early monocyte/ nificant (Fig. 9) . macrophage infiltration and predominant mesangial involvement. In support of other observations [25, 28- 29] DISCUSSION our current study demonstrates PPAR␥ DNA binding in Peroxisome proliferator activated receptor ␥ ligands isolated nuclear preparations of glomeruli from control of the thiazolidinedione group (troglitazone, pioglitaanimals. In contrast to the demonstrated up-regulation in zone, rosiglitazone) have become an important group of isolated macrophages [11] , the induction of ATS-nephritis anti-diabetic drugs in humans [6] . In experimental studreduces glomerular PPAR␥ DNA binding. However, ies in diabetic rats, PPAR␥ activators protected against treatment of nephritic animals with the PPAR␥ ligands the development and progression of diabetic nephropatroglitazone, ciglitazone and 15d-PGJ 2 significantly inthy [7, 8] . Troglitazone decreased microalbuminuria in creases the glomerular DNA binding of PPAR␥, providpatients with diabetic nephropathy [26] , but it was withing evidence that the PPAR␥ ligands in the doses used drawn from the market when reports provided evidence in our study activate glomerular PPAR␥. for unexpected aggravation of hepatitis as a side effect An important chemokine for the attraction of M/M in [27] . Although the observed renal protective effect in the anti-thymocyte antibody induced glomerulonephritis diabetes may be an indirect effect of the antidiabetic is monocyte-chemoattractant protein-1 (MCP-1) [19] [20] [21] . and antihyperlipidemic effects of PPAR␥ activators, it Its expression is positively correlated with the infiltration is possible that it results from direct effects through of monocytes/macrophages in glomeruli and blockade PPAR␥ receptors in the kidney itself. Recent studies of MCP-1 action in vivo has been demonstrated to lead have shown that PPAR␥ receptors are expressed in the to a reduction of glomerular monocytes in this model kidney [28] [29] [30] and, more specifically, in glomeruli [30] . [19, 21, 34] . In contrast to observations on isolated monoSeveral investigators have reported that PPAR␥ exprescytes/macrophages, where cytokine expression was resion can be regulated in cultured mesangial cells [30] [31] [32] .
duced by stimulation of PPAR␥ [11] , in our study of Importantly, it has been demonstrated that PPAR␥ is glomerular inflammation the PPAR␥ activators troglitazone and ciglitazone enhanced the expression of a major functionally expressed in monocytes/ macrophages and PPAR␥ activators of the TZD activate the transcription factor AP-1, which increases the expression of MCP-1, thereby leading to an enhanced glomerular M/M recruitment in this form of GN. This seems to contrast earlier findings in isolated macrophages where treatment with PPAR␥ agonists reduced TNF-␣, IL-1␤ and IL-6 synthesis induced by phorbol ester [10] , and inhibited the expression of several inflammatory response genes induced by IFN-␥ [11] . However, in a recent study in vascular smooth muscle cells PPAR␥ agonists led to enhanced AP-1 activity through activation of MEK/ERK pathways by phosphatidylinositol 3-kinase [39] . Furthermore, in mice challenged with lipopolysaccharide (LPS) PPAR␥ activation through TZD did not suppress cytokine production, but rather increased blood levels of TNF-␣ and IL-6 [13] . In this study an important difference in the effects observed when using thiazolidinediones and 15d- PPAR␥ agonists of the TZD group and 15d-PGJ 2 in this model of experimental glomerulonephritis. In contrast to the treatment with troglitazone or ciglitazone, DNA binding of NF-B was reduced and MCP-1 expression glomerular chemokine, MCP-1. Treatment with troglitawas not elevated in glomeruli of nephritic rats treated zone and ciglitazone lead to an increased number of with 15d-PGJ 2 . Hence, our results support findings of infiltrating monocytes/ macrophages. Twenty-four hours other groups where 15d-PGJ 2 was shown to exert comafter induction of the disease, the enhanced glomerular plex effects beyond PPAR␥ activation in the NF-B sig-MCP-1 formation and monocyte recruitment was paralnaling pathway. In monocytes 15d-PGJ 2 directly inhibleled with an increased glomerular RNA expression of ited the action of IB kinase independently of PPAR␥ the MCP-1 receptor CCR-2, which is predominantly exactivation [15, 16] , and recently it was demonstrated in pressed on mononuclear cells. A recent in situ hybridizahuman mesangial cells that 15d-PGJ 2 also inhibits the tion study provides evidence for the absence of CCR-2 translocation of NF-B through attenuated degradation on resident glomerular cells [35] , suggesting that the upof IkB␣ [40] . regulated glomerular CCR-2 RNA expression is due to
Because results of previous studies show possible efthe infiltration of CCR-2 positive monocytes attracted fects of PPAR␥ agonists on cell proliferation [41, 42] , by MCP-1.
we measured proliferation cell nuclear antigen (PCNA) To determine which transcription factors might be regas a marker of cell proliferation in our model of GN at 24 ulated by PPAR␥ activation in this form of glomerulonehours and five days after induction of disease. However, phritis and, more specifically, drive the expression of the glomerular PCNA determined by Western blotting and chemokine MCP-1, we investigated the glomerular DNA immunohistology was not altered significantly in nebinding of the transcription factors NF-B and AP-1.
phritic animals when they were treated with troglitazone. NF-B and AP-1 are important regulators of MCP-1
In summary, our results demonstrate that treatment gene expression [36, 37] , and recent studies have shown with the PPAR␥ agonists of the TZD group (troglitazone that PPAR␥ can directly influence the activity of NF-B and ciglitazone) but not 15d-PGJ 2 enhances MCP-1 forand AP-1 in macrophages [11] . In addition, it seems mation and M/M recruitment in the induction phase of a unlikely that PPAR␥ activation may directly regulate rat model of mesangial proliferative glomerulonephritis. the transcription of the C-C chemokine MCP-1 because Our data suggest that these effects may be partly medino PPRE element is reported in the 5Јregion of the ated through an increased binding activity of the nuclear MCP-1 gene. Our results further confirm an earlier study transcription factor AP-1. It seems possible that PPAR␥ in the ATS model of glomerulonephritis demonstrating agonists of the TZD group may lead to an enhanced an increased glomerular activation of NF-B and AP-1 attraction of inflammatory cells in glomerulonephritis. [38] . We show that the activity of NF-B was unaffected
The findings of this study underscore the need for a by troglitazone and ciglitazone, whereas the activity of careful evaluation of possible deleterious effects of PPAR␥ activators in human glomerulonephritis. AP-1 was markedly increased. Our results suggest that
